Ovid Therapeutics Inc. (OVID) News

Ovid Therapeutics Inc. (OVID): $3.45

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add OVID to Watchlist
Sign Up

Industry: Biotech


Ranked

of 504

in industry

Filter OVID News Items

OVID News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

OVID News Highlights

  • For OVID, its 30 day story count is now at 6.
  • Over the past 12 days, the trend for OVID's stories per day has been choppy and unclear. It has oscillated between 1 and 3.

Latest OVID News From Around the Web

Below are the latest news stories about Ovid Therapeutics Inc that investors may wish to consider to help them evaluate OVID as an investment opportunity.

Ovid Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological diseases, today announced that management will present in a virtual format at the H.C. Wainwright 23 rd Annual Global Investment Conference. The presentation will be made available for on-demand viewing on Monday, September 13, 2021 at 7:00 a.m. EDT.

Intrado Digital Media | September 7, 2021

Is Ovid Therapeutics Inc. (NASDAQ:OVID) Popular Amongst Insiders?

Every investor in Ovid Therapeutics Inc. ( NASDAQ:OVID ) should be aware of the most powerful shareholder groups...

Yahoo | September 6, 2021

Angelman Syndrome Market Will Hit Big Revenues in Upcoming Future by 2028| Ovid Therapeutics, GeneTx Biotherapeutics, PTC Therapeutics, Sarepta Therapeutics and StrideBio

Angelman syndrome is a genetic condition that affects the nervous system and causes severe physical and learning disabilities. A person with Angelman syndrome will have a near-normal life expectancy, but they will need support throughout their life. Angelman syndrome can result

OpenPR | August 26, 2021

Gauging Ovid Therapeutics’ Risk Factors Post Q2

Biopharmaceutical company Ovid Therapeutics Inc.'s (OVID) product pipeline is targeted at neurological disorders. Its programs under development include: OV329, targeted at seizures associated with tuberous sclerosis complex and infantile spasms; OV882 for Angelman syndrome; and OV815 for KIF1A-associated neurological disorders. Let's take a look at the company's Q2 numbers, as well as what has changed in its key risk factors that investors should be aware of. (See Ovid Therapeutics stock charts on TipRanks) Ovid did not generate any revenue during Q2. Its R&D expenses decreased to $7.

Kailas Salunkhe on TipRanks | August 23, 2021

Ovid Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights

Company ends Q2 ’21 with cash and cash equivalents of $212.2 millionRecent appointments to Company leadership strongly position Ovid to advance current and future neuroscience programsOvid is actively pursuing business development opportunities to complement its neuroscience pipeline NEW YORK, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological diseases, today r

Yahoo | August 16, 2021

Ovid Therapeutics Strengthens Board & Leadership Team to Focus Efforts on Expanding Its Neurosciences Capabilities

Dr. Michael Poole to Join the Board of Directors Dr. Claude Nicaise Appointed Head of R&D and Jason Tardio Appointed Chief Operating Officer Dr. Amit Rakhit to Join the Scientific and Clinical Advisory Board NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID) today announced appointments to its board of directors and leadership team as well as a realignment of its workforce to focus on early-stage development activities, including the build out of its neuroscience p

Yahoo | July 8, 2021

Ovid Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference

NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will present in a virtual format at the Ladenburg Thalmann 2021 Healthcare Conference on Wednesday, July 14, 2021 at 9:30 a.m. ET. A live webcast of the virtual presentation can be accessed through the Events & Presentations section of the Company’s websi

Yahoo | July 7, 2021

Should Weakness in Ovid Therapeutics Inc.'s (NASDAQ:OVID) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

It is hard to get excited after looking at Ovid Therapeutics' (NASDAQ:OVID) recent performance, when its stock has...

Yahoo | July 6, 2021

Ovid Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

Closed royalty, license and termination agreement with Takeda for soticlestat; Ovid Therapeutics received an upfront payment of $196.0 million and is eligible to receive up to $660.0 million in additional milestone payments, plus tiered double-digit royalties, up to 20%, on sales if soticlestat is commercializedEnding Q1’21 cash and cash equivalents balance of $233.1 million and reduced cash burn supports prioritization of resources to advance robust early-stage neuroscience pipeline and explore full ecosystem of complementary external innovation Company is actively pursuing business development opportunities to advance its early-stage neuroscience pipeline and is planning to evaluate clinical stage assets that support its mission to bring innovative therapies to rare neurological disor...

Yahoo | May 13, 2021

Ovid Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference

NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 9:10 a.m. ET. A live audio webcast of the virtual fireside chat can be accessed through the Events & Presentations section of the Company’s website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company’s website following the live presentation. About Ovid Therapeutics Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develo...

Yahoo | May 12, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7228 seconds.